16 / 38
CNS activity with front-line EGFR TKIs
not applicable, NA; brain metastases, BM; hazard ratio, HR, confidence interval, CI
Trial
FLAURA
ARCHER 1050
LUX-7
Drug
Osimertinib Gefitinib/
Erlotinib
Dacomiti
nib
Gefitinib Afatinib Gefitinib
CNS mets (%)
19
23
Excluded
16
16
Dose reduction
(%)
4
5
66
0
42
2
PFS HR (95%CI)
BM+
0.47 (0.30-0.74)
NA
0.76 (0.41-1.44)
PFS HR (95%CI)
BM-
0.46 (0.36-0.59)
NA
0.74 (0.56-0.98)
Park K et al Lancet Oncol 2016; Paz-Arez L et al Ann Oncol 2017; Wu YL et al Lancet Oncol 2017; Mok T et al J Clin Oncol 2018; Soria JC et al NEJM 2017; Furuya N et al J
Clin Oncol 2018 (abstract 9006); Seto T et al Lancet Oncol 2014; Yamamoto N et al J Clin Oncol 2018 (abstract 9007); Nakamura A et al J Clin Oncol 2018 (abstract 9005)